Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-0476, montelukast · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Montelukast sodium | EXPERIMENTAL | Participants receive montelukast sodium for 14 days. |
| Name | Type | Description |
|---|---|---|
| MK-0476, montelukast sodium | DRUG | Duration of Treatment: 14 Days |
Inclusion Criteria : * Active bronchiolitis or a history of bronchiolitis and asthma-like symptoms Exclusion Criteria : * A history of any significant illness that will pose additional risk to the patient
MK-0476, also known as montelukast, is a small molecule being studied for respiratory conditions including seasonal allergic rhinitis, bronchiolitis, and bronchial asthma. It is currently in Phase 2 clinical development for these indications.
MK-0476 is a small molecule being developed for respiratory conditions. Its specific molecular target has not been disclosed in available clinical trial information.
MK-0476 is being developed by Organon & Co., a company traded on the New York Stock Exchange under the ticker symbol OGN.
MK-0476 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities for the conditions under study.
MK-0476 has been studied in completed clinical trials, including NCT00092105 for asthma and perennial allergic rhinitis, NCT00092885 for seasonal allergic rhinitis with asthma, and NCT00394069 for bronchiolitis in young children.
Yes, MK-0476 is also known as montelukast. Clinical trials reference montelukast sodium as the study drug, and the compound is being evaluated for respiratory indications.